envafolimab

Overview

Envafolimab (KN035) is a subcutaneously administered single-domain antibody (nanobody) targeting PD-L1 (CD274). Its subcutaneous formulation distinguishes it from conventional intravenous anti-PD-L1 antibodies and is under investigation in NPC.

Evidence in the corpus

• Envafolimab + CCRT in locally advanced NPC: phase II ORR 94.4%; cited among ICIs being combined with concurrent chemoradiation PMID:24952746.
• Comparative efficacy of subcutaneous envafolimab vs intravenous ICIs in NPC is noted as unstudied PMID:24952746.

Resistance mechanisms

Cancer types (linked)

• NPC

Sources

This page was processed by entity-page-writer on 2026-05-11.